Quoin Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Quoin Pharmaceuticals, Inc.

Oct-30	Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 QNRX GlobeNewswire
Oct-28	Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing Study QNRX GlobeNewswire
Oct-21	Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome QNRX GlobeNewswire
Oct-10	Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million QNRX GlobeNewswire
Sep-09	Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome QNRX GlobeNewswire
Aug-21	Quoin Pharmaceuticals' NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome QNRX GlobeNewswire
Aug-18	Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy QNRX GlobeNewswire
Aug-12	Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton QNRX GlobeNewswire
Aug-07	Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update QNRX GlobeNewswire
Jul-31	Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 QNRX GlobeNewswire
Jul-29	Quoin Pharmaceuticals Provides Product Portfolio Update QNRX GlobeNewswire
Jun-26	Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases QNRX GlobeNewswire
Jun-24	Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome QNRX GlobeNewswire
May-22	Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study QNRX GlobeNewswire
May-20	Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome QNRX GlobeNewswire
May-14	Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study QNRX GlobeNewswire
May-13	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results QNRX GlobeNewswire
May-06	Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 QNRX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.